Edinah Mudimu1, Kathryn Peebles2, Zindoga Mukandavire3,4, Emily Nightingale5, Monisha Sharma2, Graham F Medley5, Daniel J Klein6, Katharine Kripke7, Anna Bershteyn6,8. 1. Department of Decision Sciences, University of South Africa, Pretoria, South Africa. 2. Department of Global Health, University of Washington, Seattle, WA, United States of America. 3. Centre for Data Science, Coventry University, Coventry, United Kingdom. 4. School of Computing, Electronics and Mathematics, Coventry University, Coventry, United Kingdom. 5. Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom. 6. Institute for Disease Modeling, Seattle, WA, United States of America. 7. Avenir Health, Washington, District of Columbia, United States of America. 8. Department of Population Health, New York University Grossman School of Medicine, NY, United States of America.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV and has the potential to significantly impact the HIV epidemic. Given limited resources for HIV prevention, identifying PrEP provision strategies that maximize impact is critical. METHODS: We used a stochastic individual-based network model to evaluate the direct (infections prevented among PrEP users) and indirect (infections prevented among non-PrEP users as a result of PrEP) benefits of PrEP, the person-years of PrEP required to prevent one HIV infection, and the community-level impact of providing PrEP to populations defined by gender and age in western Kenya and South Africa. We examined sensitivity of results to scale-up of antiretroviral therapy (ART) and voluntary medical male circumcision (VMMC) by comparing two scenarios: maintaining current coverage ("status quo") and rapid scale-up to meet programmatic targets ("fast-track"). RESULTS: The community-level impact of PrEP was greatest among women aged 15-24 due to high incidence, while PrEP use among men aged 15-24 yielded the highest proportion of indirect infections prevented in the community. These indirect infections prevented continue to increase over time (western Kenya: 0.4-5.5 (status quo); 0.4-4.9 (fast-track); South Africa: 0.5-1.8 (status quo); 0.5-3.0 (fast-track)) relative to direct infections prevented among PrEP users. The number of person-years of PrEP needed to prevent one HIV infection was lower (59 western Kenya and 69 in South Africa in the status quo scenario; 201 western Kenya and 87 in South Africa in the fast-track scenario) when PrEP was provided only to women compared with only to men over time horizons of up to 5 years, as the indirect benefits of providing PrEP to men accrue in later years. CONCLUSIONS: Providing PrEP to women aged 15-24 prevents the greatest number of HIV infections per person-year of PrEP, but PrEP provision for young men also provides indirect benefits to women and to the community overall. This finding supports existing policies that prioritize PrEP use for young women, while also illuminating the community-level benefits of PrEP availability for men when resources permit.
BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV and has the potential to significantly impact the HIV epidemic. Given limited resources for HIV prevention, identifying PrEP provision strategies that maximize impact is critical. METHODS: We used a stochastic individual-based network model to evaluate the direct (infections prevented among PrEP users) and indirect (infections prevented among non-PrEP users as a result of PrEP) benefits of PrEP, the person-years of PrEP required to prevent one HIV infection, and the community-level impact of providing PrEP to populations defined by gender and age in western Kenya and South Africa. We examined sensitivity of results to scale-up of antiretroviral therapy (ART) and voluntary medical male circumcision (VMMC) by comparing two scenarios: maintaining current coverage ("status quo") and rapid scale-up to meet programmatic targets ("fast-track"). RESULTS: The community-level impact of PrEP was greatest among women aged 15-24 due to high incidence, while PrEP use among men aged 15-24 yielded the highest proportion of indirect infections prevented in the community. These indirect infections prevented continue to increase over time (western Kenya: 0.4-5.5 (status quo); 0.4-4.9 (fast-track); South Africa: 0.5-1.8 (status quo); 0.5-3.0 (fast-track)) relative to direct infections prevented among PrEP users. The number of person-years of PrEP needed to prevent one HIV infection was lower (59 western Kenya and 69 in South Africa in the status quo scenario; 201 western Kenya and 87 in South Africa in the fast-track scenario) when PrEP was provided only to women compared with only to men over time horizons of up to 5 years, as the indirect benefits of providing PrEP to men accrue in later years. CONCLUSIONS: Providing PrEP to women aged 15-24 prevents the greatest number of HIV infections per person-year of PrEP, but PrEP provision for young men also provides indirect benefits to women and to the community overall. This finding supports existing policies that prioritize PrEP use for young women, while also illuminating the community-level benefits of PrEP availability for men when resources permit.
Authors: Linda-Gail Bekker; Surita Roux; Elaine Sebastien; Ntando Yola; K Rivet Amico; James P Hughes; Mark A Marzinke; Craig W Hendrix; Peter L Anderson; Vanessa Elharrar; Michael Stirratt; James F Rooney; Estelle Piwowar-Manning; Susan H Eshleman; Laura McKinstry; Maoji Li; Bonnie J Dye; Robert M Grant Journal: Lancet HIV Date: 2017-10-03 Impact factor: 12.767
Authors: Anna Bershteyn; Jaline Gerardin; Daniel Bridenbecker; Christopher W Lorton; Jonathan Bloedow; Robert S Baker; Guillaume Chabot-Couture; Ye Chen; Thomas Fischle; Kurt Frey; Jillian S Gauld; Hao Hu; Amanda S Izzo; Daniel J Klein; Dejan Lukacevic; Kevin A McCarthy; Joel C Miller; Andre Lin Ouedraogo; T Alex Perkins; Jeffrey Steinkraus; Quirine A Ten Bosch; Hung-Fu Ting; Svetlana Titova; Bradley G Wagner; Philip A Welkhoff; Edward A Wenger; Christian N Wiswell Journal: Pathog Dis Date: 2018-07-01 Impact factor: 3.166
Authors: Christopher M Mayer; Asiphas Owaraganise; Jane Kabami; Dalsone Kwarisiima; Catherine A Koss; Edwin D Charlebois; Moses R Kamya; Maya L Petersen; Diane V Havlir; Britta L Jewell Journal: J Int AIDS Soc Date: 2019-04 Impact factor: 5.396
Authors: Christian Selinger; Anna Bershteyn; Dobromir T Dimitrov; Blythe J S Adamson; Paul Revill; Timothy B Hallett; Andrew N Phillips; Linda-Gail Bekker; Helen Rees; Glenda Gray Journal: Vaccine Date: 2019-03-16 Impact factor: 3.641
Authors: Andrew N Phillips; Anna Bershteyn; Paul Revill; Loveleen Bansi-Matharu; Katharine Kripke; Marie-Claude Boily; Rowan Martin-Hughes; Leigh F Johnson; Zindoga Mukandavire; Lise Jamieson; Gesine Meyer-Rath; Timothy B Hallett; Debra Ten Brink; Sherrie L Kelly; Brooke E Nichols; Eran Bendavid; Edinah Mudimu; Isaac Taramusi; Jennifer Smith; Shona Dalal; Rachel Baggaley; Siobhan Crowley; Fern Terris-Prestholt; Peter Godfrey-Faussett; Irene Mukui; Andreas Jahn; Kelsey K Case; Diane Havlir; Maya Petersen; Moses Kamya; Catherine A Koss; Laura B Balzer; Tsitsi Apollo; Thato Chidarikire; John W Mellors; Urvi M Parikh; Catherine Godfrey; Valentina Cambiano Journal: Lancet HIV Date: 2022-05 Impact factor: 16.070
Authors: Anna Bershteyn; Lise Jamieson; Hae-Young Kim; Ingrida Platais; Masabho P Milali; Edinah Mudimu; Debra Ten Brink; Rowan Martin-Hughes; Sherrie L Kelly; Andrew N Phillips; Loveleen Bansi-Matharu; Valentina Cambiano; Paul Revill; Gesine Meyer-Rath; Brooke E Nichols Journal: Lancet Glob Health Date: 2022-09 Impact factor: 38.927
Authors: John Stover; Sherrie L Kelly; Edinah Mudimu; Dylan Green; Tyler Smith; Isaac Taramusi; Loveleen Bansi-Matharu; Rowan Martin-Hughes; Andrew N Phillips; Anna Bershteyn Journal: PLoS One Date: 2021-12-23 Impact factor: 3.240